FOR 12:49 CONFORMATION DISCLOSURE STATEMENT	Docket Number: 14233.19USWO		
1	Applicant: Lautt et al.		
IN AN APPLICATION (Use several sheets if necessary)	Filing Date: July 21, 2004		
MIN (Use several sinces it incesses)			

& TRADEMA			U.S	. PATENT DOCUMEN	TS T			
AMINER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
NITIAL								
	 							
	<u> </u>							
	<u> </u>		FORI	EIGN PATENT DOCUM	MENTS			
		IT NO	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	DOCUMENT NO.	DAIL		_		YES	NO	
	1 020 452		06/26/1998	EP			 	
	1 142 879		12/20/1999	EP		<u> </u>	 	
	02/13798		02/21/2002	wo		<u> </u>	ļ	
	02/24698		03/28/2002	wo		<u> </u>		
	03/028730		04/10/2003	wo				<u> </u>
		ОТНЕР	R DOCUMENT	S (Including Author, Title	e, Date, Pertinen	t Pages, Etc.)		
		Evans et	al., (2001) "Insu	lin resistance and β -cell d 3: 219-229.	ysfunction as the	erapeutic targets in		
	-	Lautt et a	al., (1998) "Rapi	d insulin sensitivity test (l	RIST)", Can. J. I	Physiol. Pharmaco	1., 76: 1080-10	086.
		Lautt (19	999) "The HISS s	story overview: a novel he Can. J. Physiol. Pharmace	epatic neurohum ol., 77: 553-562.	oral regulation of p	eripheral insu	in sensitiv
		Nakaya	et al. (1999) "Cil	ostazol, a phosphodiester	ase inhibitor, im ous NIDDM", D	, ,		
			,	othelial Nitric Oxide Pro	duction and Insu	lin Sensitivity", Cit	rculation, 93:	1331-1333

23552
PATENT TRADEMARK OFFICE

DATE CONSIDERED 03/14/2008 /Sahar Javanmard/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Sheet 1 of 1

Application Number: 10/502,119

Group Art Unit: 1632